Skip to content
Tazemetostat
Tazverik (tazemetostat) is a small molecule pharmaceutical. Tazemetostat was first approved as Tazverik on 2020-01-23. The pharmaceutical is active against histone-lysine N-methyltransferase EZH2.
Download report
Favorite
FDA Novel Drug Approvals 2020
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Tazverik
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Tazemetostat hydrobromide
Tradename
Company
Number
Date
Products
TAZVERIKEpizymeN-211723 RX2020-01-23
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
tazverikNew Drug Application2020-07-31
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration
Code
TAZEMETOSTAT HYDROBROMIDE, TAZVERIK, EPIZYME INC
2027-06-18ODE-314
2027-01-23ODE-299
2025-01-23NCE
2023-06-18I-835, I-836
Patent Expiration
Patent
Expires
Flag
FDA Information
Tazemetostat Hydrobromide, Tazverik, Epizyme Inc
107865112035-12-19DP
98891382035-10-16U-2736, U-2852, U-2853
103691552035-10-16U-2736, U-2852, U-2853
96886652034-08-22U-2736
84100882034-01-23DS, DP
93942832033-04-11DS, DPU-2852, U-2853
98728622033-04-11U-2738
102452692033-04-11U-2737, U-2851, U-2854
108211132033-04-11DS, DP
114911632033-04-11U-3491, U-3492
87657322032-04-13U-2852, U-2853
90905622032-04-13DS, DP
95221522032-04-13U-2738
95499312032-04-13U-2736, U-2852, U-2853
98552752032-04-13U-2736
101550022032-04-13U-2736
104207752032-04-13U-2736, U-2852, U-2853
110520932032-04-13DS, DPU-2736, U-3179
86915072031-09-12U-2852
88952452031-09-12U-2852
91753312031-09-12U-2852
93332172031-09-12U-2852
93345272031-09-12U-2852
99499992031-09-12U-2851
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01X: Other antineoplastic agents in atc
— L01XX: Other antineoplastic agents in atc
— L01XX72: Tazemetostat
HCPCS
No data
Clinical
Clinical Trials
49 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
SarcomaD012509361—210
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Follicular lymphomaD008224C8297——111
NeoplasmsD009369C8065———9
Non-hodgkin lymphomaD008228C85.965———9
Rhabdoid tumorD01833534———6
Large b-cell lymphoma diffuseD016403C83.362———6
Synovial sarcomaD01358432———4
MesotheliomaD008654C4522———3
Prostatic neoplasmsD011471C6131———3
ChordomaD002817EFO_000033412——13
LymphomaD008223C85.921———2
Show 31 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Mantle-cell lymphomaD020522C83.12————2
Hematologic neoplasmsD0193371————1
Hepatic insufficiencyD0485501————1
Hepatocellular carcinomaD006528C22.01————1
Castration-resistant prostatic neoplasmsD0641291————1
Myeloid leukemia acuteD015470C92.01————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Small cell carcinomaD018288————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameTAZEMETOSTAT
INNtazemetostat
Description
Tazemetostat, sold under the brand name Tazverik, is a medication used for the treatment of adults and adolescents aged 16 years and older with metastatic (when cancer cells spread to other parts of the body) or locally advanced (when cancer has grown outside the organ it started in, but has not yet spread to distant parts of the body) epithelioid sarcoma not eligible for complete resection (surgically removing all of a tissue, structure, or organ).
Classification
Small molecule
Drug classenzyme inhibitors
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CCN(c1cc(-c2ccc(CN3CCOCC3)cc2)cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)C1CCOCC1
Identifiers
PDB—
CAS-ID1403254-99-8
RxCUI—
ChEMBL IDCHEMBL3414621
ChEBI ID—
PubChem CID66558664
DrugBankDB12887
UNII IDQ40W93WPE1 (ChemIDplus, GSRS)
Target
Agency Approved
EZH2
EZH2
Organism
Homo sapiens
Gene name
EZH2
Gene synonyms
KMT6
NCBI Gene ID
2146
Protein name
histone-lysine N-methyltransferase EZH2
Protein synonyms
Enhancer of zeste homolog 2, ENX-1, Lysine N-methyltransferase 6
Uniprot ID
Q96FI6
Mouse ortholog
Ezh2 (14056)
histone-lysine N-methyltransferase EZH2 (Q9R090)
Alternate
No data
Variants
Clinical Variant
No data
Financial
Tazemetostat - Epizyme
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 1,351 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
1,003 adverse events reported
View more details